Table 2.
cGVHD characteristics
| N (% or range) | |
|---|---|
| All patients | 193 |
| cGVHD onseta | |
| Progressive | 77 (40) |
| Quiescent | 50 (26) |
| De novo | 65 (34) |
| Median days from transplant to cGVHD Dx | 211 (51–2482) |
| Median days from cGVHD Dx to consent | 696 (0–6670) |
| cGVHD organ involvementb | |
| Skin | 152 (79) |
| Joints and fascia | 122 (63) |
| Eyes | 161 (83) |
| Mouth | 129 (67) |
| Lungs | 150 (77) |
| Liver | 95 (49) |
| GI | 86 (45) |
| Genital (females only, n = 95) | 45 (47) |
| Number of organs affected by cGVHD | Median 5 (range 1–8) |
| 1–2 affected organs | 11 (6) |
| 3–4 affected organs | 82 (42) |
| 5–6 affected organs | 77 (40) |
| 7–8 affected organs | 24 (12) |
| NIH Global scorec | |
| Mild | 5 (3) |
| Moderate | 58 (30) |
| Severe | 130 (68) |
| Prior cGVHD systemic treatment regimens | |
| <2 | 21 (11) |
| 2–3 | 71 (37) |
| 4–5 | 59 (31) |
| >5 | 38 (20) |
| Intensity of immunosuppressiond | |
| None/mild | 47 (24) |
| Moderate | 72 (37) |
| Severe | 73 (38) |
| Activity by therapeutic intente | |
| Active | 78 (40) |
| Non-active | 77 (40) |
| Other | 38 (20) |
Abbreviations: Dx = diagnosis; GI = gastrointestinal; NIH = National Institutes of Health.
Definition for cGVHD onset: progressive (acute GVHD progressed directly to cGVHD); quiescent (acute GVHD resolved, then chronic GVHD developed); de novo (acute GVHD never developed).
cGVHD organ involvement per NIH Organ Score.9
Definition for NIH Global score as follows: mild (1–2 organs affected by cGVHD with scores 1); moderate (more than 2 organs with score 1, any score 2 or lung score 1) or severe (any score of 3 or lung score of 2).9
Definition of intensity of immunosuppression is as follows: mild (single-agent prednisone 0.5 mg/kg per day); moderate (single agent prednisone 0.5 mg/kg per day and/or any single agent/modality); high (two or more agents/modalities +/ − prednisone 0.5 mg/kg per day).21
Definition of activity by therapeutic intent is as follows: active (increase systemic therapy because cGVHD is worse, substitute systemic therapy because of lack of response or withdraw systemic therapy because of lack of response); non-active (decrease systemic therapy because cGVHD is better, not change current systemic therapy because cGVHD is stable or alter systemic therapy owing to its toxicity); other (either did not receive any immunosuppressive therapy or did not meet any of the criteria).10